Vanguard Portfolio Management’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
Other funds holding BEAM
KCM
Vanguard Portfolio Management's BEAM Position: Q3 2026 in Review
Vanguard Portfolio Management reduced its Beam Therapeutics (BEAM) stake by 0.4% in Q3 2026, selling an estimated $546K and leaving 4,901,651 shares worth $120M. The position accounts for 0.01% of the portfolio, ranked #1412.
Vanguard Portfolio Management first reported a position in BEAM in Q1 2026 and has held it in 3 quarters since. The position peaked at $169M in Q2 2026. 264 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.
- Vanguard Portfolio Management held 4,901,651 shares of Beam Therapeutics worth $120M as of Q3 2026.
- Vanguard Portfolio Management sold 19,608 Beam Therapeutics shares in Q3 2026, an estimated $546K.
- Beam Therapeutics made up 0.01% of Vanguard Portfolio Management's portfolio in Q3 2026, its #1412 holding.
- Vanguard Portfolio Management first reported a position in Beam Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Portfolio Management's Beam Therapeutics position peaked at $169M in Q2 2026.
- 264 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.
Based on Vanguard Portfolio Management's 13F filing for Q3 2026, filed 13 Nov 2026.